Abacavir/lamivudine/zidovudine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abacavir/lamivudine/zidovudine
Abacavir, lamivudine and zidovudine.svg
Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleoside analogue reverse transcriptase inhibitor
Zidovudine Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names Trizivir
AHFS/Drugs.com FDA Professional Drug Information
MedlinePlus a687007
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
KEGG
NIAID ChemDB
 NYesY (what is this?)  (verify)

Abacavir/lamivudine/zidovudine, sold under the trade name Trizivir, is a medication for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[2]

It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir.[5][6] As of 2016 the wholesale cost for a typical month of medication in the United States is more than 669.30 USD.[7]

See also[edit]

References[edit]

  1. ^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases. 185 (9): 1251–1260. PMID 12001042. doi:10.1086/340312. 
  2. ^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture Archived January 4, 2012, at the Wayback Machine.
  3. ^ Drugs.com: Trizivir
  4. ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". Cochrane Database Syst Rev (1): CD006734. PMID 19160297. doi:10.1002/14651858.CD006734.pub2. 
  5. ^ Monthly Prescribing Reference (MPR)
  6. ^ Lupin Pharma
  7. ^ "NADAC as of 2016-12-07 | Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Retrieved 12 December 2016.